There has long been a discussion about the possible effects of using testosterone as a treatment for men with advanced metastatic prostate cancer. In a poster presentation at ASCO 2019, it was shown that there are androgen receptor changes in the circulating-tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone.